WAM
CORT icon

Wealthspire Advisors (Maryland)’s Corcept Therapeutics CORT Stock Holding History

Wealthspire Advisors (Maryland)’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-259
Closed -$3K – 777
2019
Q1 		$3K Sell
259
-15
-5% -$186 ﹤0.01% 1985
2018
Q4 		$4K Buy
274
+55
+25% +$727 ﹤0.01% 1798
2018
Q3 		$3K Buy
219
+36
+20% +$503 ﹤0.01% 2010
2018
Q2 		$3K Buy
+183
New +$3.18K ﹤0.01% 1985

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Wealthspire Advisors (Maryland)'s CORT Position: Q2 2019 in Review

Wealthspire Advisors (Maryland) sold out of Corcept Therapeutics (CORT) in Q2 2019, closing a stake of 259 shares — an estimated $3K sold.

Wealthspire Advisors (Maryland) first reported a position in CORT in Q2 2018 and held it in 4 quarters. The position peaked at $4K in Q4 2018. 183 funds tracked by Wall St. Rank hold CORT as of Q2 2019.

  • Wealthspire Advisors (Maryland) reported no remaining Corcept Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Wealthspire Advisors (Maryland) sold 259 Corcept Therapeutics shares in Q2 2019, an estimated $3K.
  • Wealthspire Advisors (Maryland) first reported a position in Corcept Therapeutics in Q2 2018 and held it in 4 quarters.
  • Wealthspire Advisors (Maryland)'s Corcept Therapeutics position peaked at $4K in Q4 2018.
  • 183 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2019.

Based on Wealthspire Advisors (Maryland)'s 13F filing for Q2 2019, filed 12 Aug 2019.